Ivabradine Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 5 mg, 7.5 mg, and 9 mg
Reference Brands: Corlanor(US), Procoralan(EU)
Category:
Heart Disorder
Ivabradine selectively inhibits funny current (If) channels in the sinoatrial node, lowering heart rate without affecting blood pressure or ventricular contractility. It reduces angina attacks, improves exercise tolerance, and decreases hospitalization risk in chronic heart failure. Benefits include better heart rate control, symptom relief, and improved quality of life.
Ivabradine tablet is available in Tablet
and strengths such as 5 mg, 7.5 mg, and 9 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ivabradine tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ivabradine tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ivabradine tablets, marketed as Corlanor (US) and Procoralan (EU), are approved for chronic stable angina and heart failure management. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and quality information, while the EMA ensures compliance with safety and manufacturing standards across European regions. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regional regulatory adherence supports timely approval, safe use, and worldwide availability of ivabradine tablets, helping improve heart rate management and reduce cardiovascular events globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing